Skip to Content
Merck
CN
  • Inhibition of lung inflammatory responses by bornyl acetate is correlated with regulation of myeloperoxidase activity.

Inhibition of lung inflammatory responses by bornyl acetate is correlated with regulation of myeloperoxidase activity.

The Journal of surgical research (2013-10-15)
Na Chen, Guoquan Sun, Xue Yuan, Jinli Hou, Qianchao Wu, Lanan W Soromou, Haihua Feng
ABSTRACT

Bornyl acetate is a bicyclic monoterpene present in numerous conifer oils. In this study, we aimed at clarifying the potential anti-inflammatory function and mechanism of bornyl acetate by using lipopolysaccharide (LPS)-induced acute lung injury murine model and RAW 264.7 cells. RAW 264.7 cells were pretreated with bornyl acetate 1 h before LPS stimulation and cell-free super supernatants were collected to measure cytokine concentrations. To induce acute lung injury, BALB/c mice were injected intranasally with LPS and treated with bornyl acetate 1 h before LPS stimulation. Seven hours after administration, the bronchoalveolar lavage fluid (BALF) was collected for measuring the cell count and cytokine production. We collected lungs for assaying wet-to-dry weight ratio, myeloperoxidase activity, and histologic changes. The extent of phosphorylation of mitogen-activated protein kinases and nuclear factor κB was detected by Western blot. Our results showed that bornyl acetate downregulated the levels of proinflammatory cytokines in vitro and in vivo; reduced the number of total cells, neutrophils, and macrophages in BALF; attenuated the histologic alterations in the lung; decreased the wet-to-dry weight ratio in BALF; and suppressed NF-kappa-B inhibitor alpha, extracellular regulated protein kinases, c-JunN-terminal kinase, p38 mitogen-activated protein kinase activation. These findings suggested that bornyl acetate may be developed as a preventive agent for lung inflammatory diseases.